Drugs / Iparomlimab/Tuvonralimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07454018 | Mar 2026 → Dec 2029 expected | carcinoma, ovarian cancer | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab/Tuvonralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07454018 ↗ |
| Known as | QL1706 | “This is a prospective, open-label, single-arm, multicenter exploratory clinical study designed to evaluate the efficacy and safety of iparomlimab/tuvonralimab (QL1706), a...” NCT07454018 ↗ |
| Route | Intravenous | “Iparomlimab/Tuvonralimab administered intravenously in 3-week cycles per protocol” NCT07454018 ↗ |